The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Abstract
Purpose: To assess the cardiac status of the long-term survivors and to estimate the incidence and the features of subclinical cardiotoxicity induced after conventional treatment with doxorubicin for non-Hodgkin's lymphoma or Hodgkin's lymphoma. Patients and Methods: We analyzed a group of patients who previously received doxorubicin-based chemotherapy for lymphoma. Echocardiograms were performed at least 5 years after therapy with anthracyclines. Clinical cardiomyopathy was defined by the presence of clinical signs of congestive heart failure (CHF). Subclinical cardiomyopathy was defined by decrease of left ventricular fractional shortening (FS) without clinical signs of CHF. Cumulative dose of doxorubicin, male sex, older age, relapse, radiotherapy (mediastinal or total-body irradiation), autologous stem-cell transplantation, high-dose cyclophosphamide, and cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia, familial history of cardiac disease, being overweight, and smoking history) were evaluated as potential risk factors for the development of cardiac dysfunction. Results: Of 141 assessable patients (median age, 54 years; median cumulative dose of doxorubicin, 300 mg/m 2), only one developed CHF. Criteria of subclinical cardiomyopathy were found in 39 patients. In multivariate analysis, factors that contributed to decreased FS were male sex (P < .01), older age (P < .01), higher cumulative dose of doxorubicin or association with another anthracycline (P = .04), radiotherapy (P = .04), and being overweight (P = .04). Conclusion: Cardiac abnormalities can occur in patients treated with doxorubicin for lymphoma in the absence of CHF, even in patients who received moderate anthracycline doses. Male sex, older age, higher dose of doxorubicin, radiotherapy, and being overweight were risk factors for the development of cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Mosterd, A. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1239 · Cited by 674
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
BRISTOW, M. R., MASON, J. W., BILLINGHAM, M. E., & DANIELS, J. R. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-2-168 · Cited by 417
Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf167 · Cited by 354
Hensley, M. L., Schuchter, L., Lindley, C., Meropol, N., Cohen, G., Broder, G., Gradishar, W., Green, D., Langdon, R., Mitchell, R. B., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3333 · Cited by 335
Steinherz, L. J., Graham, T., Hurwitz, R., Sondheimer, H. M., Schwartz, R. G., Shaffer, E. M., Sandor, G., Benson, L., & Williams, R. (1992) · Pediatrics · doi:10.1542/peds.89.5.942 · Cited by 327
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B. V., & Dombernowsky, P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3502 · Cited by 289
The Epidemiology of Asymptomatic Left Ventricular Systolic Dysfunction: Implications for Screening
Wang, T. J., Levy, D., Benjamin, E. J., & Vasan, R. S. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-11-200306030-00012 · Cited by 229
Sorensen, K., Levitt, G., Bull, C., Chessells, J., & Sullivan, I. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.61 · Cited by 160
Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphoma
Limat, S., Demesmay, K., Voillat, L., Bernard, Y. F., Deconinck, É., Brion, A., Rebibo-Sabbah, A., Woronoff-Lemsi, M. C., & Cahn, J.-Y. Y. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg070 · Cited by 133
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Anderlini, P. N., Benjamin, R. S., Wong, F. C. S., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2827 · Cited by 123
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
Friedman, M. A. (1978) · JAMA · doi:10.1001/jama.240.15.1603 · Cited by 112
Ehler, D., CARNEY, D., Dempsey, A. L., Rigling, R., Kraft, C. D., Witt, S. A., Kimball, T. R., Sisk, E. J., Geiser, E. A., & Gresser, C. D. (2001) · Journal of the American Society of Echocardiography · doi:10.1067/mje.2001.109922 · Cited by 103
Friedman, M. (1978) · JAMA · doi:10.1001/jama.1978.03290150049023 · Cited by 95
Monoclonal gammopathies in adult T-cell leukemia
Matsuzaki, H., Yamaguchi, K., Kagimoto, T., Nakai, R., Takatsuki, K., & Oyama, W. (1985) · Cancer · doi:10.1002/1097-0142(19850915)56:6<1361::aid-cncr2820560624>3.0.co;2-s · Cited by 36
Baker, D. W., Bahler, R. C., Finkelhor, R. S., & Lauer, M. S. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00396-x · Cited by 36
Anthracycline‐induced cardiotoxicity in children with malignancies
GODOY, L. Y., Fukushige, J., Igarashi, H., Matsuzaki, A., & Ueda, K. (1997) · Pediatrics International · doi:10.1111/j.1442-200x.1997.tb03579.x · Cited by 28
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Metadata
- Authors
- Hequet, O., Le, Q. H., Moullet, I., Pauli, E., Salles, G., Espinouse, D., Dumontet, C., Thieblemont, C., Arnaud, P., Antal, D., Bouafia, F., & Coiffier, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-05-15
- Volume
- 22
- Issue
- 10
- Pages
- 1864-1871
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107401114
- Cited by
- 340
- References
- 23
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.